Phio Pharmaceuticals Corp (PHIO) Stock Price, Quote & News

Company Profile

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RX...

Industry: Biotechnology

Sector: Healthcare

Phone: 610 947 0251

Website: phiopharma.com

Address:

411 Swedeland Road, Suite 23-1080, King of Prussia, United States

DosGatos Jul. 13 at 7:57 PM

$PHIO

1 · Reply

Stonkey Jul. 10 at 1:09 PM

$PHIO Under a dollar in 3......2......1...... Yes, brainless little pumpers....

1 · Reply

PitaPierogi Jul. 9 at 9:23 PM

$PHIO Calling it "untested" is simply inaccurate. PH-762 has already gone through extensive preclinical testing and completed a Phase 1b clinical trial in human patients. The FDA doesn't allow a drug into human trials without substantial supporting data. It's fair to say it isn't approved or fully proven yet, that's what later-stage trials are for, but calling it "untested" is misleading.

2 · Reply

HaroldH Jul. 9 at 12:31 PM

$PHIO Pumpers just never stop! Something, sorta good might happen sorta soon. Please stop. You people are embarrassing. I understand that the science looks promising, although untested as yet, but its the financing that is of concern as well the timeliness of their delivery.

2 · Reply

Abdullah_1697 Jul. 9 at 6:19 AM

📊 Watchlist — Signals from 7/8/26, 30-bar swing $AUTL Entry: 1.71 Stop: 1.50 (-11.8%) TP2R: 2.13 | TP3R: 2.34 $PHIO Entry: 1.08 Stop: 0.93 (-13.8%) TP2R: 1.38 | TP3R: 1.53 $OIS Entry: 8.37 Stop: 7.24 (-13.5%) TP2R: 10.63 | TP3R: 11.76 Personal notes, not investment advice.

1 · Reply

DosGatos Jul. 9 at 1:20 AM

$PHIO pumpers are stirring!

2 · Reply

Avennite Jul. 8 at 9:28 PM

$PHIO during the last presentation Bob mentioned that phase 2 will take place in q1 of 2027. Based on that they have to have FDA engagement soon.

1 · Reply

PitaPierogi Jul. 7 at 8:41 PM

$PHIO fda news, possible buyout news. Companies got absorbed by bigger Pharmaceuticals with less data.

1 · Reply

HaroldH Jul. 7 at 8:36 AM

$PHIO CEO purchases are often taken to be bullish for a stock. In the case of Bob B the history is: 18 Nov 2025 5000 @ $1.27 21 Nov 2025 5000 @ $1.14 23 Dec 2025 5000 @ $1.02 31 Dec 2025 5000 @ 1.03 26 June 2026 10000 @ 0.99 Notice the price trend is downwards not upwards. Thus, his purchases seem to be signalling a concern about the short term price trend being downward rather than bullish excitement about the future. Ignore this analysis at your peril.

3 · Reply

HaroldH Jul. 7 at 8:15 AM

$PHIO Nothing has changed since my last posts. I remain bearish.

3 · Reply

Phio Pharmaceuticals Transcript: Fireside chat

Jun 26, 2026, 7:00 AM EDT - 18 days ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Jun 25, 2026, 3:00 PM EDT - 18 days ago

Phio Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum

Jun 24, 2026, 7:00 AM EDT - 20 days ago

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762

May 7, 2026, 4:05 PM EDT - 2 months ago

Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

May 7, 2026, 7:00 AM EDT - 2 months ago

Phio Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Phio Pharmaceuticals Earnings release: Q1 2026

Apr 15, 2026, 12:00 PM EDT - 3 months ago

Phio Pharmaceuticals Transcript: Fireside chat

Apr 14, 2026, 10:30 AM EDT - 3 months ago

Phio Pharmaceuticals Transcript: Second Annual Centri Capital Conference

Apr 13, 2026, 7:00 AM EDT - 3 months ago

Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

Mar 23, 2026, 7:00 AM EDT - 4 months ago

Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement

Mar 16, 2026, 11:30 AM EDT - 4 months ago

Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office

Mar 12, 2026, 11:00 AM EDT - 4 months ago

Phio Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum

Mar 10, 2026, 8:35 AM EDT - 4 months ago

Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT

Mar 10, 2026, 7:00 AM EDT - 4 months ago

Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT

Mar 5, 2026, 4:05 PM EST - 4 months ago

Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update

Mar 5, 2026, 4:00 PM EST - 4 months ago

Phio Pharmaceuticals Annual report: Q4 2025

Mar 5, 2026, 4:00 PM EST - 4 months ago

Phio Pharmaceuticals Earnings release: Q4 2025

Feb 24, 2026, 7:00 AM EST - 5 months ago

Phio Pharmaceuticals Slides: Corporate presentation

Feb 10, 2026, 7:00 AM EST - 5 months ago

Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial

Jan 26, 2026, 8:15 AM EST - 6 months ago

Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

Jan 20, 2026, 9:30 AM EST - 6 months ago

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

Jan 15, 2026, 8:45 AM EST - 6 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026

Dec 23, 2025, 8:45 AM EST - 7 months ago

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Nov 25, 2025, 11:30 AM EST - 8 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

2025-11-20T21:11:11.000Z - 8 months ago

Phio Pharmaceuticals files to sell 11.76M shares of common stock for holders

Nov 20, 2025, 7:00 AM EST - 8 months ago

Phio Pharmaceuticals Registration statement: Registration Filing

Nov 17, 2025, 8:45 AM EST - 8 months ago

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 13, 2025, 4:15 PM EST - 8 months ago

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 7:00 AM EST - 8 months ago

Phio Pharmaceuticals Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Phio Pharmaceuticals Quarterly report: Q3 2025

Nov 7, 2025, 10:30 AM EST - 8 months ago

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025, 7:45 AM EST - 8 months ago

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 3, 2025, 1:40 PM EST - 9 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

2025-11-03T14:24:44.000Z - 9 months ago

Why Is Phio Pharmaceuticals Stock Up 75% Today?

Nov 3, 2025, 7:45 AM EST - 9 months ago

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Oct 31, 2025, 10:15 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Sep 18, 2025, 7:45 AM EDT - 10 months ago

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 3, 2025, 7:45 AM EDT - 11 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 8:00 AM EDT - 11 months ago

Phio Pharmaceuticals Proxy statement: Proxy Filing

Aug 15, 2025, 8:00 AM EDT - 11 months ago

Phio Pharmaceuticals Registration statement: Registration Filing

2025-08-15T10:10:23.000Z - 11 months ago

Phio Pharmaceuticals files to sell 1.93M shares of common stock for holders

Aug 14, 2025, 4:15 PM EDT - 11 months ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Phio Pharmaceuticals Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Phio Pharmaceuticals Quarterly report: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Proxy statement: Proxy Filing

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Proxy statement: Proxy Filing

Jul 25, 2025, 3:04 PM EDT - 1 year ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 12:36 PM EDT - 1 year ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jun 25, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 24, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 6, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

2025-06-05T10:15:09.000Z - 1 year ago

Phio Pharmaceuticals assumed with a Buy at H.C. Wainwright

May 19, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 15, 2025, 4:15 PM EDT - 1 year ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Earnings release: Q1 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Quarterly report: Q1 2025

May 7, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Apr 9, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 3, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Mar 31, 2025, 4:00 PM EDT - 1 year ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Earnings release: Q4 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Annual report: Q4 2024

Mar 10, 2025, 7:45 AM EDT - 1 year ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 5, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Feb 20, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Jan 22, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

2025-01-21T21:45:15.000Z - 1 year ago

Phio Pharmaceuticals files to sell 5.93M shares of common stock for holders

Jan 21, 2025, 4:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 21, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Registration statement: Registration Filing

Jan 16, 2025, 1:00 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2025-01-16T16:10:29.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

AZTR BDTX ERNA GTBP IBIO KAPA SLXN

2025-01-15T16:15:41.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

ARDX CGEN CLRB IBIO MRNA

Jan 15, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2025-01-14T14:40:47.000Z - 1 year ago

Phio Pharmaceuticals Corp trading resumes

2025-01-14T14:35:14.000Z - 1 year ago

Phio Pharmaceuticals Corp trading halted, volatility trading pause

Jan 14, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 13, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 2, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Dec 23, 2024, 1:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 14, 2024, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Quarterly report: Q3 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Phio Pharmaceuticals Earnings release: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Phio Pharmaceuticals Quarterly report: Q2 2024

2024-07-26T20:33:23.000Z - 2 years ago

Phio Pharmaceuticals files to sell 1.13M shares of common stock for holders

Jul 26, 2024, 8:00 AM EDT - 2 years ago

Phio Pharmaceuticals Registration statement: Registration Filing

2024-07-08T14:05:37.000Z - 2 years ago

Phio Pharmaceuticals Corp trading resumes

2024-07-08T14:00:37.000Z - 2 years ago

Phio Pharmaceuticals Corp trading halted, volatility trading pause

2024-07-03T20:50:02.000Z - 2 years ago

Phio Pharmaceuticals Corp trading halted, news pending

2024-05-20T21:05:00.000Z - 2 years ago

Phio Pharmaceuticals files $100M mixed securities shelf

May 20, 2024, 8:00 AM EDT - 2 years ago

Phio Pharmaceuticals Registration statement: Registration Filing

2024-05-17T20:46:48.000Z - 2 years ago

Phio Pharmaceuticals files $100M mixed securities shelf

2024-05-17T13:02:30.000Z - 2 years ago

Phio Pharmaceuticals entered into purchase agreement with TRITON Funds

DosGatos Jul. 13 at 7:57 PM

$PHIO

1 · Reply

Stonkey Jul. 10 at 1:09 PM

$PHIO Under a dollar in 3......2......1...... Yes, brainless little pumpers....

1 · Reply

PitaPierogi Jul. 9 at 9:23 PM

2 · Reply

HaroldH Jul. 9 at 12:31 PM

2 · Reply

Abdullah_1697 Jul. 9 at 6:19 AM

1 · Reply

DosGatos Jul. 9 at 1:20 AM

$PHIO pumpers are stirring!

2 · Reply

Avennite Jul. 8 at 9:28 PM

$PHIO during the last presentation Bob mentioned that phase 2 will take place in q1 of 2027. Based on that they have to have FDA engagement soon.

1 · Reply

PitaPierogi Jul. 7 at 8:41 PM

$PHIO fda news, possible buyout news. Companies got absorbed by bigger Pharmaceuticals with less data.

1 · Reply

HaroldH Jul. 7 at 8:36 AM

3 · Reply

HaroldH Jul. 7 at 8:15 AM

$PHIO Nothing has changed since my last posts. I remain bearish.

3 · Reply

trader_23 Jul. 7 at 1:02 AM

$PHIO

0 · Reply

uptrend2025 Jul. 6 at 3:21 PM

$PHIO One of these days 👀

3 · Reply

Philarney Jul. 5 at 3:30 PM

$PHIO Phio Pharmaceuticals (NASDAQ: $PHIO ) to present its INTASYL® siRNA platform and PH-762 program at the Life Sciences Investor Forum on June 24-25, 2026. Phio Pharmaceuticals Corp. (NASDAQ: PHIO) will participate in the Life Sciences Investor Forum on June 24-25, 2026. CEO and Chairman Robert Bitterman will present an overview of the Company’s INTASYL® siRNA gene silencing platform

0 · Reply

Philarney Jul. 5 at 3:29 PM

$PHIO

0 · Reply

Philarney Jul. 5 at 3:29 PM

$PHIO

0 · Reply

Philarney Jul. 5 at 3:29 PM

$PHIO nice

0 · Reply

Philarney Jul. 5 at 3:29 PM

$PHIO